Ranbaxy Adr Rises After Usfda Nod
On September 16, the news of Ranbaxy receiving the US FDA nod to market an oral suspension drug, Cephalexin, led to a major upswing in the company
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 17 2003 | 12:00 AM IST